Supplementary Tables – Incidence of safety events after immune checkpoint inhibitor initiation for advanced-stage non-small-cell lung cancer: a real-world study

<strong>Supplemental Table 1:</strong> Code lists for safety event algorithms <strong>Supplemental Table 2. </strong>Incidence of safety events by case definition in the overall cohort (n=44,045) <br> <strong>Supplemental Table 3</strong>: Incidence of safety events by case definition before and after the start of ICIs in the advanced-stage NSCLC cohort <strong>Supplemental Table 4</strong>: Incidence of selected safety events in the first 6 months and after 6 months of ICIs in the advanced-stage NSCLC cohort (N=5,278)